Pharmacogenetics in the Brazilian population

Frontiers in Pharmacology

Volumn OCT, Issue , 2010, Pages

  Suarez Kurtz, Guilherme ^a  

^a INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

Biogeographical ancestry; Brazilian pharmacogenetic network; HIV protease inhibitors; Non steroidal anti inflammatory drugs; Population admixture; Warfarin

Indexed keywords

EID: 79961161857     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2010.00118     Document Type: Article

References (47)

1. Bastos-Rodrigues, L., Pimenta, J. R., and Pena, S. D. J. (2006). The genetic structure of human populations studied through short insertion-deletion polymorphisms. Ann. Hum. Genet. 70, 658-665.
2. Estrela, R. C. E., Ribeiro, F. S., Carvalho, R. S., Gregorio, S. P., Dias-Netto, E., Struchiner, C. J., and Suarez-Kurtz, G. (2008a).The distribution of ABCB1 polymorphisms among Brazilians: Impact of population admixture. Pharmacogenomics 9, 267-276.
3. Estrela, R. C. E., Santoro, A. B., Barroso, P. F., Tuyama, M., and Suarez-Kurtz, G. (2008b). CYP3A5 genotype has no impact on plasma trough concentrations of lopinavir and ritonavir in HIV-infected subjects. Clin. Pharmacol. Ther. 84, 205-207.
4. Estrela, R. C. E., Ribeiro, F. S., Barroso, P. F., Tuyama, M., Gregório, S. P., Dias-Neto, E., Struchiner, C. J., and Suarez-Kurtz. G. (2009). ABCB1 polymorphisms have no impact on the concentrations of lopinavir and ritonavir in blood, semen and saliva of HIV-infected men under stable antiretroviral therapy. Pharmacogenomics 10, 311-318.
5. Gage, B. F., Eby, C., Johnson, J. A., Deych, E., Rieder, M. J., Ridker, P. M., Milligan, P. E., Grice, G., Lenzini, P., Rettie, A. E., Aquilante, C. L., Grosso, L., Marsh, S., Langaee, T., Farnett, L. E., Voora, D., Veenstra, D. L., Glynn, R. J., Barrett, A., and McLeod, H. L. (2008). Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331.
6. Hartkoorn, R. C., Kwan, W. S., Shallcross, V., Chaikan, A., Liptrott, N., Egan, D., Sora, E. S., James, C. E., Gibbons, S., Bray, P. G., Back, D. J., Khoo, S. H., and Owen, A. (2010). HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms. Pharmacogenet. Genomics 20, 112-120.
7. Hutz, M. H., and Fiegenbaum, M. (2008). Impact of genetic polymorphisms on the efficacy of HMG-CoA reductase inhibitors. Am. J. Cardiovasc. Drugs 8, 161-170.
8. IWPC, The International Warfarin Pharmacogenetic Consortium, Klein, T. E., Altman, R. B., Eriksson, N., Gage, B. F., Kimmel, S. E., Lee, M. T., Limdi, N. A., Page, D., Roden, D. M., Wagner, M. J., Caldwell, M. D., and Johnson, J. A. (2009). Estimation of the warfarin dose with clinical and pharmacogenetic data. New Engl. J. Med. 360, 753-764.
9. Jaja, C., Burke, W., Thummel, K., Edwards, K., and Veenstra, D. L. (2008). Cytochrome p450 enzyme polymorphism frequency in indigenous and native american populations, a systematic review. Community Genet. 11, 141-149.
10. Josephson, F., Allqvist, A., Janabi, M., Sayi, J., Aklillu, E., Jande, M., Mahindi, M., Burhenne, J. Bottiger, Y., Gustafsson, L. L., Haefeli, W. E., and Bertilsson, L. (2007). CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin. Pharmacol. Ther. 81, 708-712.
11. Kalow, W. (1962). Pharmacogenetics, Heredity and the Response to Drugs. Philadelphia: WB Saunders Co.
12. Kieling, C., Genro, J. P., Hutz, M. H., and Rohde, L. A. (2010). A current update on ADHD pharmacogenomics. Pharmacogenomics 11, 407-419.
13. Kohlrausch, F. B., Estrela, R. C. E., Barroso, P. F., and Suarez-Kurtz, G. (2010). The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-infected men. Br. J. Clin. Pharmacol. 69, 95-98.
14. Kohlrausch, F. B., Salatino-Oliveira, A., Gama, C. S., Lobato, M. I., Belmonte-de-Abreu, P., and Hutz, M. H. (2008). G-protein gene 825C > T polymorphism is associated with response to clozapine in Brazilian schizophrenics. Pharmacogenomics 9, 1429-1436.
15. McDonald, M. G., Rieder, M. J., Nakano, M., Hsia, C. K., and Rettie, A. E. (2009). CYP4F2 is a vitamin K1 oxidase, An explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346.
16. McLeod, H. L. (2007). "Pharmacogenetics in the African American population," In Pharmacogenomics in Admixed Populations, ed. G. Suarez-Kurtz (Austin, TX: Landes Bioscience). 47-59.
17. Nagassaki, S., Herculano, R. D., Graeff, C. F., and Tanus-Santos, J. E. (2009). eNOS T-786C polymorphism affects atorvastatin-induced changes in erythrocyte membrane fluidity. Eur. J. Clin. Pharmacol. 65, 385-392.
18. Parra, E. J. (2007). "Admixture in north America," in Pharmacogenomics in Admixed Populations, ed. G. Suarez-Kurtz (Austin, TX: Landes Bioscience), 28-46.
19. Parra, F. C., Amado, R. C., Lambertucci, J. R., Rocha, J., Antunes, C. M., and Pena, S. D. J. (2003). Color and genomic ancestry in Brazilians. Proc. Natl. Acad. Sci. USA 100, 177-182.
20. Patrinos, A. (2004). 'Race' and the human genome. Nat. Genet. 36 (Suppl), S1-S2.
21. Pena, S. D. J. (2007). "The evolution and structure of human genetic diversity," in Pharmacogenomics in Admixed Populations, ed. G. Suarez-Kurtz (Austin, TX: Landes Bioscience), 1-11.
22. Pena, S. D., Bastos-Rodrigues, L., Pimenta, J. R., and Bydlowski, S. P. (2009). DNA tests probe the genomic ancestry of Brazilians. Braz. J. Med. Biol. Res. 42, 870-876.
23. Perini, J. A., Struchiner, C. J., Silva-Assunção, E., Santana, I. S. C., Rangel, F., Ojopi, E. B., Dias-Neto, E., and Suarez-Kurtz, G. (2008a). Pharmacogenetics of warfarin: development of a dosing algorithm for Brazilian patients. Clin. Pharmacol. Ther. 84, 722-728.
24. Perini, J. A., Petzl-Erler, M. L., Tsuneto, L. T., and Suarez-Kurtz, G. (2008b). VKORC1 polymorphisms in Amerindian populations of Brazil. Pharmacogenomics 9, 1623-1629.
25. Perini, J. A., Struchiner, C. J., Silva-Assunção, E., and Suarez-Kurtz, G. (2010). Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. Clin. Pharmacol. Ther. 87, 417-420.
26. Perini, J. A., and Suarez-Kurtz, G. (2006). Impact of CYP2C9*3/*3 genotype on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 80, 549-551.
27. Perini, J. A., Vargens, D. D., Santana, I. S., Moriguchi, E. H., Ribeiro-Dos-Santos, A. K., Tsutsumi, M., and Suarez-Kurtz, G. (2009). Pharmacogenetic polymorphisms in Brazilian-born, first-generation Japanese descendants. Braz. J. Med. Biol. Res. 42, 1179-1184.
28. Perini, J. A., Vianna-Jorge, R., Brogliato, A. R., and Suarez-Kurtz, G. (2005). Influence of CYP2C9 genotypes on the pharmacokinetics and pharmacodynamics of piroxicam. Clin. Pharmacol. Ther. 78, 362-369.
29. Pritchard, J. K., Stephens, M., and Donnelly, P. (2000). Inference of population structure using multilocus genotype data. Genetics 155, 945-959.
30. Rebecchi, I. M., Rodrigues, A. C., Arazi, S. S., Genvigir, F. D., Willrich, M. A., Hirata, M. H., Soares, S. A., Bertolami, M. C., Faludi, A. A., Bernik, M. M., Dorea, E. L., Dagli, M. L., Avanzo, J. L., and Hirata, R. D. (2009). ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem. Pharmacol. 77, 66-75.
31. Ribeiro, D. (1995). O Povo Brasileiro, a Formação e o Sentido do Brasil. São Paulo: Companhia das Letras.
32. Rodrigues, A. C., Hirata, M. H., and Hirata, R. D. (2007). The genetic determinants of atorvastatin response. Curr. Opin. Mol. Ther. 9, 545-553.
33. Salzano, F. M., and Bortolini, M. C. (2002). A Study of Brazilian Populations. Detroit: Wayne State University Press.
34. Sandrim, V. C., Palei, A. C., Luizon, M. R., Izidoro-Toledo, T. C., Cavalli, R. C., and Tanus-Santos, J. E. (2010). eNOS haplotypes affect the responsiveness to antihypertensive therapy in preeclampsia but not in gestational hypertension. Pharmacogenomics J. 10, 40-45.
35. Suarez-Kurtz, G. (2004). Pharmacogenomics in admixed populations, the Brazilian pharmacogenetics/pharmacogenomics network - REFARGEN. Pharmacogenomics J. 4, 347-438.
36. Suarez-Kurtz, G. (2005). Pharmacogenetics in admixed populations. Trends Pharmacol. Sci. 26, 196-201.
37. Suarez-Kurtz, G. (2008a). The implications of population admixture in race-based therapy. Clin. Pharmacol. Ther. 3, 399-400.
38. Suarez-Kurtz, G. (2008b). Ethnic differences in drug therapy, a pharmacogenomics perspective. Expert Rev. Clin. Pharmacol. 1, 337-339.
39. Suarez-Kurtz, G., Amorim, A., Damasceno, A., Hutz, M. H., Moraes, M. O., Ojopi, E. B., Pena, S. D. J., Perini, J. A., Prata, M. J., Ribeiro-dos-Santos, A., Romano-Silva, M. A., Teixeira, D., and Struchiner, C. J. (2010a). VKORC1 polymorphisms in Brazilians, comparison with the Portuguese and Portuguese-speaking Africans and pharmacogenetic implications. Pharmacogenomics 11, 1257-1267.
40. Suarez-Kurtz, G., Genro, J. P., Moraes, M. O., Ojopi, E. B., Pena, S. D. J., Perini, J. A., Ribeiro-dos-Santos, A., Romano-Silva, M. A., Santana, I., and Struchiner, C. J. (2010b). Global pharmacogenomics: Impact of population diversity on the distribution of polymorphisms in the CYP2C cluster among Brazilians. in preparation.
41. Suarez-Kurtz, G., and Pena, S. D. J. (2006). Pharmacogenomics in the Americas, Impact of genetic admixture. Curr. Drug Targets 7, 1649-1658.
42. Suarez-Kurtz, G., and Pena, S. D. J. (2007). "Pharmacogenetic studies in the Brazilian population" in Pharmacogenomics in Admixed Populations, ed. G. Suarez-Kurtz (Austin, TX: Landes Bioscience), 75-98.
43. Suarez-Kurtz, G., Vargens, D. D., Struchiner, C. J., Bastos-Rodrigues, L., and Pena, S. D. J. (2007a). Self-reported skin color, genomic ancestry and the distribution of GST polymorphisms. Pharmacogenet. Genomics 17, 765-771.
44. Suarez-Kurtz, G., Perini, J. A., Bastos-Rodrigues, L., Pena, S. D. J., and Struchiner, C. J. (2007b). Impact of population admixture on the distribution of the CYP3A5*3 polymorphism. Pharmacogenomics 8, 1299-1306.
45. Suarez-Kurtz, G., Perini, J. A., Silva-Assunção, E., and Struchiner, C. J. (2009). Relative contribution of VKORC1, CYP2C9 and INR response to warfarin stable dose. Blood 113, 4125-4126.
46. Vargens, D. D., Almendra, L., Struchiner, C. J., and Suarez-Kurtz, G. (2008). Distribution of the GNB3 825C > T polymorphism among Brazilians, impact of population structure. Eur. J. Clin. Pharmacol. 3, 253-256.
47. Vianna-Jorge, R., Perini, J. A., Rondinelli, E., and Suarez-Kurtz, G. (2004). CYP2C9 genotypes and the pharma-cokinetics of tenoxicam in Brazilians. Clin. Pharmacol. Ther. 76, 18-26.